Superior Mesenteric Artery Syndrome as a Rare Cause of Postoperative Intractable Vomiting: A Case Report [0.03%]
术后难治性呕吐的罕见原因-肠系膜上动脉综合症一例报告
Sanketh Edem,Aakansha Giri Goswami,Bibek Karki et al.
Sanketh Edem et al.
Background: Superior mesenteric artery syndrome is a very rare cause of proximal intestinal obstruction. The objective of this clinical case report is to highlight that this unusual condition can occur in the early postop...
A Multicentre Study of the Clinical and Epidemiological Profile of Inflammatory Bowel Disease in Northeast Brazil [0.03%]
巴西东北部炎症性肠病的临床和流行病学特征的多中心研究
Carlos Alexandre Antunes de Brito,Lívia Medeiros Soares Celani,Marcelo Vicente Toledo de Araújo et al.
Carlos Alexandre Antunes de Brito et al.
Purpose: Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBDs) with multifactorial causes. They are becoming more prevalent in developing countries such as Brazil; however, relevant studi...
Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management [0.03%]
应用于便秘型肠易激综合征治疗的tenapanor：发现、疗效及管理作用
Anam Herekar,Dhanush Shimoga,Asad Jehangir et al.
Anam Herekar et al.
Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction (DGBI). IBS significantly impacts the quality of life of patients. Since its pathogenesis is unclear and can be multifactorial, it highlights the need for new and ...
David J Cangemi,Brian E Lacy
David J Cangemi
Gastroparesis (GP), a historically vexing disorder characterized by symptoms of nausea, vomiting, abdominal pain, early satiety, and/or bloating, in the setting of an objective delay in gastric emptying, is often difficult to treat and carr...
Susceptibility of PCSK2 Polymorphism to Hirschsprung Disease in Southern Chinese Children [0.03%]
PCSK2多态性与南方汉族儿童先天性巨结肠病的相关性研究
Bingtong Wang,Wenlin Fang,Dingjiang Qin et al.
Bingtong Wang et al.
Introduction: Hirschsprung's disease (HSCR) is a developmental defect of the enteric nervous system (ENS), which is caused by abnormal development of enteric neural crest cells. Its occurrence is caused by genetic factors...
A Novel Multidisciplinary Team Activation for Patients with Severe Gastrointestinal Bleeding: Creation of the Code GI Bleed Protocol [0.03%]
一种针对严重胃肠出血患者的新型多学科团队激活方法：创建代码胃肠出血协议
Christopher W Baugh,Aaron D Sodickson,Sean M Kivlehan et al.
Christopher W Baugh et al.
Patients with gastrointestinal (GI) bleeding present to the emergency department (ED) with a wide spectrum of illness severity. Among the most critically ill patients, comorbidities and other risk factors, such as liver disease and anticoag...
Esophageal Mucosal Admittance: A New Technique to Diagnose Gastroesophageal Reflux Disease - Is It Feasible? [0.03%]
食管粘膜导电量：一种诊断胃食管反流病的新技术吗？可行吗？
Hang Viet Dao,Long Bao Hoang,Binh Phuc Nguyen et al.
Hang Viet Dao et al.
Purpose: Esophageal mucosal admittance (MA) is a promising diagnostic method for gastroesophageal reflux disease (GERD). We conducted a study to describe the esophageal MA in patients with reflux symptoms and determine it...
Symptomatic Uncomplicated Diverticular Disease (SUDD): Practical Guidance and Challenges for Clinical Management [0.03%]
有症状的简单结肠 diverticulosis(SUDD)：临床处理的实用建议和挑战
Giacomo Calini,Mohamed A Abd El Aziz,Lucia Paolini et al.
Giacomo Calini et al.
Symptomatic Uncomplicated Diverticular Disease (SUDD) is a syndrome within the diverticular disease spectrum, characterized by local abdominal pain with bowel movement changes but without systemic inflammation. This narrative review reports...
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes [0.03%]
乌帕替尼治疗中至重度活动性溃疡性结肠炎成人患者的临床评价：患者选择和报告结果
Malcolm Irani,Christopher Fan,Kerri Glassner et al.
Malcolm Irani et al.
This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the ...
Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors [0.03%]
瑞普特尼布治疗胃肠间质瘤安全性和有效性的最新研究数据
Prapassorn Thirasastr,Neeta Somaiah
Prapassorn Thirasastr
In patients with gastrointestinal stromal tumors (GIST), systemic treatment after disease progression on imatinib is challenging. Sunitinib and regorafenib are approved in the second- and third-line setting, respectively, with activity agai...